Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2023-12-01 00:00:00 ET · period of report 2023-05-31 · accession 0001787306-23-000129 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-01 | 2023-12-01 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | M - OptEx | $1.68 | +59.5K | 513.7K | +13% | +$100.0K |
| D | 2023-12-01 | 2023-05-31 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | P - Purchase | $6.38 | +1,463 | 515.1K | +0.3% | +$9,334 |
| D | 2023-12-01 | 2023-12-01 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | M - OptEx | $0.00 | -59.5K | 49.8K | -54% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-01 | M | A | 59,525 | $1.68 | 513,682 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-31 | P | A | 1,463 | $6.38 | 515,145 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-12-01 | M | D | 59,525 | $0.00 | 49,823 | D | $1.68 · — to 2029-03-13 | 59,525 Common Stock | (F1) The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. |